Medicure Reports Financial Results for Quarter Ended March 31, 2021

b'WINNIPEG, May 10, 2021 /PRNewswire/ -Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), acompany focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2021.\nRecorded total net revenue of $4.9 million during the quarter ended March 31, 2021 compared to $3.0 million for the quarter ended March 31, 2020 and;\nRecorded total net revenue from the sale of AGGRASTAT of $2.6 million during the quarter ended March 31, 2021 compared to $2.7 million for the quarter ended March 31, 2020 and;\nDiversified product portfolio with revenues from the Marley Drug business of $2.1 million and ZYPITAMAGrevenues of $161,000 during the quarter ended March 31, 2021 and;\nAdjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended March 31, 2021 was $31,000 compared to adjusted EBITDA of negative $1.3 million for the quarter ended March 31, 2020 and;\nNet loss for the quarter ended March 31, 2021 was $1.0 million compared to $1.5 million for the quarter ended March 31, 2020.\nAGGRASTAT revenues were consistent when compared to the same period in the previous year.